Treats hypertension. ANDA 203821, held by Glenmark Pharmaceuticals. Nebivolol Hydrochloride.
As of Nov 21, 2026, ANDA 203821 (Nebivolol Hydrochloride), held by Glenmark Pharmaceuticals, was first approved by FDA on May 25, 2017, with 2 approved supplements and 0 published complete response letters.
Nebivolol tablets are a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1.1 Hypertension
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 25, 2017 | Original application | Approved |
| Nebivolol HydrochlorideEQ 2.5MG BASE · tablet;oral | Nebivolol Hydrochloride | Rx |
| Nebivolol HydrochlorideEQ 5MG BASE · tablet;oral | Nebivolol Hydrochloride | Rx |
| Nebivolol HydrochlorideEQ 10MG BASE · tablet;oral | Nebivolol Hydrochloride | Rx |
| Nebivolol HydrochlorideEQ 20MG BASE · tablet;oral | Nebivolol Hydrochloride | Rx |
| Sep 20, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 26, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 25, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters